How should a botulinum toxin type A transdermal patch be applied, left in place for 24 hours, and then removed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Botulinum toxin “patch” use

Do not use a “botulinum toxin type A transdermal patch” at all—no such FDA‑approved patch exists; botulinum toxin A should be administered only by injection per the drug label, and transdermal delivery remains experimental. 1, 2

What to do (to protect morbidity, mortality, and quality of life)

  • If your intent is therapeutic/cosmetic BoNT‑A:
    • Use labeled intramuscular injections with onabotulinumtoxinA per FDA instructions (doses, dilution, needle, and injection sites). Do not attempt any patch application. 1
  • If your concern is botulism exposure/illness:
    • This is treated with IV botulinum antitoxin (BAT), not with any BoNT‑A product or patch. Early antitoxin reduces paralysis progression and ICU time. Contact public health/CDC immediately for BAT. 3

Why a “24‑hour toxin patch” is inappropriate

  • FDA labels specify BoNT‑A is for injection; units are not interchangeable and transdermal use is unsupported. Using a patch risks uncontrolled absorption, diffusion to unintended muscles, and serious adverse effects. 1
  • Transdermal BoNT‑A is investigational (animal and formulation studies only); no approved human patch products exist. 2, 4
  • Transdermal systems favor small molecules; BoNT‑A is a large protein and does not reliably cross intact skin. 5, 6

If someone already applied a “toxin patch”

  • Remove it immediately; wash the area with soap and water.
  • Monitor for systemic botulinum effects (ptosis, dysphagia, dysarthria, dyspnea, descending weakness). If present, urgently contact health department/CDC for botulism consultation and BAT. Early treatment improves outcomes. 3

Common pitfalls to avoid

  • Do not improvise patches or topical formulations of BoNT‑A.
  • Do not substitute BoNT‑A injection products for BAT in suspected botulism. 3
  • Do not compare “units” across toxin brands or routes. Follow the exact injection label. 1

References

Guideline

clinical guidelines for diagnosis and treatment of botulism, 2021.

MMWR Recommendations and Reports, 2021

Research

A Brief Review on Transdermal Patches.

Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, 2025

Research

Practical considerations for optimal transdermal drug delivery.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2012

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.